Project Title:
Therapeutic Targeting of CEACAM5 in Small Cell or Neuroendocrine Prostate Cancer: Molecular Correlates and Preclinical Optimization
Project Overview:
Small cell or neuroendocrine prostate cancer (SCNPC) represents an aggressive subtype of prostate cancer with a significant unmet need for new and effective therapeutics. Dr. Schweizer and team have studied an antibody drug conjugate called IMMU-30, which can target molecules overexpressed in a majority of recent SCNPC cases. Dr. Schweizer will conduct a Phase I/II study to evaluate and examine the safety, efficacy, and biomarkers associated with response to IMMU-30 in men with SCNPC. This comprehensive, multipronged study will develop a suite of non-invasive tools to characterize the biologic importance of SCNPC, will inform larger recruitment strategies for future trials, and will take a step forward in deploying precision medicine approaches for men with SCNPC.
Principle Investigators:
Fred Hutchinson Cancer Research Center Human Biology
John Lee, MD, PhD
Additional Investigators:
Fred Hutchinson Cancer Research Center Human Biology
Peter Nelson, MD
Michael Haffner, MD, PhD
Fred Hutchinson Cancer Research Center Public Health Sciences Division
Qian (Vicky) Wu, PhD
Dana Farber Cancer Institute
Himisha Beltran, MD